What's breaking now, across thousands of outlets.
The purchase of the $500 million Missouri nonprofit includes a 10-year, $200 million capital commitment, and is expected to bring Ardent at least $30 million annual EBITDA by its third year.
We haven't written up this one. Fierce Healthcare has the full story — the link below goes straight to it.
AstraZeneca has withdrawn its European marketing application for a monoclonal antibody in a subset of amyloidosis patients.
Middle-aged men should undergo regular screening for prostate cancer, the American Cancer Society said Thursday in a major change to its guidelines.
Middle-aged men should undergo regular screening for prostate cancer, the American Cancer Society said Thursday in a major change to its guidelines.
Gavi and partners have intensified a grassroots immunisation campaign in Abuja to identify and vaccinate zero-dose children in underserved communities.
Final results from the phase 2 PECATI clinical trial demonstrate encouraging long-term survival outcomes with the combination of lenvatinib and pembrolizumab in patients with previously treated…
(MedPage Today) -- Statin therapy delivered a statistical near miss at lowering risks of hepatic decompensation and liver cancer in patients with compensated cirrhosis, the phase III SACRED trial…
